Clinical bottom line
Relapsed or refractory large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy remains a significant clinical challenge with limited standard options. Emerging targeted therapies, including novel antibody-drug conjugates, bispecific antibodies, and small molecule inhibitors, show promise in this setting but require further validation. Radiotherapy may have a role as a salvage or bridging strategy post-CAR T failure. Current evidence supports a personalized approach integrating these modalities, guided by molecular profiling and patient fitness, to improve outcomes in this difficult-to-treat population (Nagler et al., 2023; Weiss et al., 2025).
What the evidence shows
CAR T-cell therapy targeting CD19 has revolutionized treatment for relapsed/refractory aggressive LBCL, but up to 50% of patients experience disease progression or relapse after treatment (Nagler et al., 2023). Management of these patients is complex due to limited approved salvage options and heterogeneous resistance mechanisms.
Recent molecular insights highlight pathways driving CAR T resistance, including antigen loss, immune evasion, and tumor microenvironment factors, suggesting targeted agents may overcome these barriers (Weiss et al., 2025). Bispecific antibodies engaging CD3 and CD20 or CD19 have demonstrated encouraging response rates in early-phase trials post-CAR T failure, offering an off-the-shelf immunotherapy alternative (Nagler et al., 2023).
Antibody-drug conjugates targeting CD79b or CD19 provide cytotoxic payload delivery with manageable toxicity profiles and have shown activity in relapsed LBCL, including post-CAR T relapse (Weiss et al., 2025). Small molecule inhibitors targeting BCL2, BTK, or epigenetic regulators are under investigation to address specific resistance pathways identified by molecular profiling.
Radiotherapy, traditionally used for localized relapse, is increasingly recognized as a salvage or bridging option post-CAR T failure, potentially enhancing local control and systemic immune responses (Review for "The Role of Radiotherapy..." 2025). However, optimal timing, dosing, and patient selection criteria remain undefined.
Caveats and uncertainty
Most data on targeted therapies post-CAR T failure derive from early-phase or retrospective studies with small cohorts, limiting generalizability. The heterogeneity of resistance mechanisms and patient comorbidities complicate standardized treatment algorithms. Long-term safety and durability of responses to novel agents remain to be established.
Radiotherapy’s role is supported mainly by systematic literature reviews and expert opinion rather than prospective trials, underscoring the need for controlled studies to clarify its benefit and integration with systemic therapies (Review for "The Role of Radiotherapy..." 2025).
Biomarker-driven approaches to select targeted agents are promising but not yet routine in clinical practice, requiring further validation in prospective cohorts.
How this may change practice
Clinicians managing relapsed/refractory LBCL after CAR T-cell therapy should consider a multidisciplinary approach incorporating molecular profiling to identify actionable targets. Emerging bispecific antibodies and antibody-drug conjugates may become preferred salvage options as more data mature.
Radiotherapy should be considered for localized relapse or as a bridging strategy, especially in patients with limited systemic options, while awaiting or complementing targeted therapies.
Ongoing clinical trials and real-world evidence will refine sequencing and combination strategies, emphasizing personalized treatment plans balancing efficacy and tolerability.